Sanders Morris Harris’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3,600
Closed -$681K 174
2026
Q1
$681K Buy
+3,600
New +$629K 0.11% 157
2025
Q4
Sell
-3,600
Closed -$474K 161
2025
Q3
$474K Buy
+3,600
New +$432K 0.06% 174
2025
Q2
Sell
-3,600
Closed -$450K 230
2025
Q1
$450K Hold
3,600
0.07% 168
2024
Q4
$443K Hold
3,600
0.07% 176
2024
Q3
$401K Hold
3,600
0.07% 179
2024
Q2
$384K Hold
3,600
0.06% 187
2024
Q1
$434K Hold
3,600
0.08% 171
2023
Q4
$450K Hold
3,600
0.22% 121
2023
Q3
$463K Hold
3,600
0.1% 160
2023
Q2
$447K Buy
+3,600
New +$484K 0.1% 154
2023
Q1
Sell
-3,600
Closed -$574K 199
2022
Q4
$574K Hold
3,600
0.22% 104
2022
Q3
$487K Buy
+3,600
New +$547K 0.12% 138
2022
Q1
Sell
-3,600
Closed -$470K 323
2021
Q4
$470K Hold
3,600
0.08% 176
2021
Q3
$504K Hold
3,600
0.09% 164
2021
Q2
$659K Sell
3,600
-100
-3% -$17.3K 0.13% 134
2021
Q1
$599K Hold
3,700
0.13% 128
2020
Q4
$603K Hold
3,700
0.14% 132
2020
Q3
$562K Buy
+3,700
New +$459K 0.15% 124

Other funds holding JAZZ

Sanders Morris Harris's JAZZ Position: Q2 2026 in Review

Sanders Morris Harris sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 3,600 shares — an estimated $681K sold.

Sanders Morris Harris first reported a position in JAZZ in Q3 2020 and held it in 18 quarters. The position peaked at $681K in Q1 2026. 87 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Sanders Morris Harris reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sanders Morris Harris sold 3,600 Jazz Pharmaceuticals shares in Q2 2026, an estimated $681K.
  • Sanders Morris Harris first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 18 quarters.
  • Sanders Morris Harris's Jazz Pharmaceuticals position peaked at $681K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.